Highest-materiality recent filing
Modular Medical announces 1-for-30 reverse stock split to regain Nasdaq compliance
Reverse split effective 5:30am ET March 31, 2026; trading on split-adjusted basis under MODD symbol.
Modular Medical lays off 29% of workforce to cut annual costs by $3.4M
Layoff of 20 positions, representing ~29% of total workforce, effective March 12, 2026.
Modular Medical raises $12M via public offering of 68M shares and warrants
Gross proceeds ~$12M from sale of 68,098,000 shares (or pre-funded warrants) and 68,098,000 warrants at $0.1762/unit.
Authorized common shares increased from 100M to 250M (Proposal 3: 46.75M for, 5.04M against).
Modular Medical raises $4.68M in underwritten public offering of stock and warrants
Offered 12,173,000 shares of common stock and warrants for 6,086,500 shares at combined price of $0.77 per unit.
Modular Medical receives Nasdaq minimum bid price deficiency notice; 180-day cure period
Nasdaq notified Company of bid price deficiency: closing bid below $1.00 for 30 consecutive business days ending June 27, 2025.
Modular Medical raises ~$12.5M in private placement; funds MODD1 tubeless FDA submission
6,247,656 Units at $1.92/Unit; each Unit = 2 common shares + 1 warrant (exercise $1.12, 4-yr term).
Modular Medical closes $8.2M public offering of 5.45M shares at $1.50/share
Offered 5,450,573 shares at $1.50/share; gross proceeds ~$8.2M before expenses.
Modular Medical gets FDA clearance for MODD1 insulin pump; launch expected early 2025
FDA cleared the MODD1 patch pump for all adults with Type 1 and Type 2 diabetes.
Milestone 2 options (FDA clearance by Aug 1, 2024) canceled on Aug 2, 2024; no clearance received.
Modular Medical prices $10M public offering of 9.09M shares at $1.10 per share
Priced 9,090,910 shares at $1.10/share for $10M gross proceeds; over-allotment option for 1,321,989 additional shares.
Modular Medical submits MODD1 insulin pump to FDA for 510(k) clearance
Submitted MODD1 next-generation insulin pump to FDA for 510(k) clearance on Jan 19, 2024.
Modular Medical enters into $6.5M ATM sales agreement with Leerink Partners
Agreement allows sale of common stock from time to time for up to $6.5M in gross proceeds.
Modular Medical adopts FDA milestone bonus program; execs get options tied to MODD-1 clearance
CEO Besser receives 135,136 options for 510(k) submission by Jan 31, 2024; no options for clearance milestone.
Modular Medical appoints former Insulet CEO Duane DeSisto to board; William Febbo resigns
William Febbo resigned from the board effective July 5, 2023; not due to any disagreement.
Modular Medical prices upsized $9.4M public offering of units at $2.13/unit
Offering of 8,816,900 common shares and warrants for 4,408,450 shares at $2.13/unit yields gross $9.4M.
Modular Medical CEO resigns; largest shareholder's Jeb Besser appointed CEO; reaffirms FDA timeline
CEO Ellen O'Connor Vos resigned effective Feb 23, 2022; she remains on the board.
Modular Medical raises $15M in public offering, uplists to Nasdaq
Priced public offering of 2.5M units at $6.00/unit for gross proceeds of $15M; each unit = 1 share + 1 warrant.
Modular Medical announces 1-for-3 reverse stock split to meet Nasdaq listing price requirement
Reverse split ratio 1-for-3; effective Nov 29, 2021; trading symbol temporarily changes to MODDD.
Chief Commercial Officer Stephen Daly resigns, effective Sept 24; consulting arrangement planned
Stephen Daly resigned as Chief Commercial Officer, effective on or about September 24, 2021.
Modular Medical appoints Lynn O'Connor Vos as CEO; founder DiPerna becomes Chairman and President
Paul DiPerna resigned as CEO effective Aug 11, 2021; remains Chairman, President, CFO, Secretary.
Effective May 22, 2025, the board of directors (the “Board”) of Modular Medical, Inc. (the “Company”) appointed Jeffrey Goldberg as a member of the Board.
On July 5, 2023, the Board appointed Duane DeSisto, 68, to serve as a member of the Board and to chair the Compensation Committee of the Board, effective immediately.
On July 5, 2023, William Febbo resigned from the board of directors (the “Board”) of Modular Medical, Inc. (the “Company”) effective immediately.
On July 21, 2022, the Board of Directors (the “Board”) of Modular Medical, Inc. (the “Company”) appointed Kevin Schmid as Chief Operating Officer of the Company.
the Board appointed Mr. James Besser, 46, as the Company’s Chief Executive Officer
On February 23, 2022, Ellen O’Connor Vos informed the board of directors (the “Board”) of Modular Medical, Inc. (the “Company”) that she was resigning from her position as Chief Executive Officer of the Company, effective immediately
On December 31, 2021, Liam Burns resigned from his position as a member of the board of directors (the "Board") of Modular Medical, Inc. (the "Company").
Effective November 29, 2021, the board of directors (the “Board”) of Modular Medical, Inc. (the “Company”) appointed Steven Felsher and Philip Sheibley as members of the Board.
Effective November 29, 2021, the board of directors (the “Board”) of Modular Medical, Inc. (the “Company”) appointed Steven Felsher and Philip Sheibley as members of the Board.
On September 14, 2021, Stephen Daly submitted his resignation as Chief Commercial Officer of Modular Medical, Inc. (the “Company”), effective on or about September 24, 2021.
Effective August 11, 2021, the Board appointed Ellen O’Connor Vos, a member of the Board since May 18, 2021, as chief executive officer of the Company.
Effective August 11, 2021, Paul DiPerna resigned as chief executive officer of Modular Medical, Inc. (the “Company”).
Max materiality 0.90 · Median 0.55 · Most common event other_material